This conference provides a venue for professionals in the drug discovery industry and academics to get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output.
FOR IMMEDIATE RELEASE / PRURGENT
SAN DIEGO, CA – Daniel G. Sipes, Director of Advanced Automation Technologies at the Genomics Institute of the Novartis Research Foundation (GNF), to speak at GTCbio’s 5th Assay and Drug Discovery Technologies on Sept. 20-21, 2010 in San Diego, CA.
Daniel G. Sipes will give a presentation on “Cell-based Assay Miniaturization and Automation at GNF: Screening and More” at the 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio. GNF recently expanded the utilities of their proprietary automated platforms for cell-based screening more deeply into the drug discovery process. Sipe’s team has utilized GNF-built automation, as well as other commercially available technologies, to enable cost effective and rapid cell-based compound profiling. In addition, this approach has enabled scientists to run primary cell assays on a scale not otherwise practical.
Daniel G. Sipes is the Director of Advanced Automation Technologies at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, CA. He has his Master of Science, Immunology University of California, Davis.
From 1989 to 1992 Daniel worked in the Hybridoma Laboratory at Genentech, Inc. developing both tool and therapeutic monoclonal antibodies. From 1992 to 1994 attended UC Davis which resulted in an MS in Immunology. From 1994 to 1999, he worked in the Transcription Research and Automated Screening Laboratories at Ligand Pharmaceuticals in San Diego, CA. It was here that Daniel developed numerous automated cell-based assays, as well as procured and implemented new robotic systems. In late 1999, joined GNF and assisted in developing and operating GNF’s flagship miniaturized cell-based uHTS system. In 2002, joined Kalypsys, Inc., a GNF spin-off company, where he was responsible for the implementation and operation of their uHTS system (built by GNF) and compound management operations. In 2005 Daniel returned to GNF and is working with a team of scientists and engineers to develop and operate next-generation automation for cell-based profiling.
Also presenting at the Assay and Drug Discovery Technologies are prestigious organizations including Burnham Medical Research Institute, Pfizer, UCSF, AstraZeneca, UCLA, Bristol Myers Squibb, Genentech, National Institute of Advanced Science and Technology, Johnson & Johnson, Nexigen GmbH, University of Pennsylvania, Roche, UCD, Abbott, Merck, Novartis (GNF), and other leaders in the Assay and Drug Discovery Technologies industry.
5th Assay and Drug Discovery Technologies Conference features a mixture of academic, industry and public sector experts in an intimate setting that favors the showcase of data, the exchanges of ideas and networking. Professionals in the drug discovery industry and academics to can get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output. For more information, visit www.gtcbio.com.